| Old Articles: <Older 8521-8530 Newer> |
|---|
 |
The Motley Fool
July 20, 2005
Karl Thiel |
Pride and Preclinicals Biotech ArQule has surged, but take its early-stage data with a grain of salt.   |
The Motley Fool
July 20, 2005
Warren Gump |
Will Perrigo's Prescription Work? Perrigo, the nation's largest maker of private-label over-the-counter (OTC) drugs, is setting new 52-week lows. Nonetheless, if management delivers as it has over the past few years, the longer-term outlook looks promising. |
The Motley Fool
July 20, 2005
Alyce Lomax |
Apple of Your Eye? More rumors of video iPods get people buzzing about Apple. Even if Apple unveils such a device, investors need to question whether it will positively affect the iPod's runaway popularity -- or translate into more sales. |
The Motley Fool
July 20, 2005
John Reeves |
Taser Shoots a Blank -- Fool by Numbers The stun gun maker released second quarter earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... |
The Motley Fool
July 20, 2005
Seth Jayson |
Inside Intel -- Fool by Numbers The chip maker released second quarter earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
July 20, 2005
Tom Taulli |
Motorola on the Razr's Edge The fight for the global share of mobile phones is intense. After much work -- and creative energy -- Motorola is climbing back. Investors, take note. |
The Motley Fool
July 20, 2005
Tom Taulli |
Lucent Still in Transition The telecom player anticipates growth, but it may take a while. Is it too long for investors to wait? |
The Motley Fool
July 20, 2005
Stephen D. Simpson |
Is United Technologies Underappreciated? Despite a solid collection of businesses, United Technologies hasn't always gotten a lot of love. But as commercial construction and aviation recover, the company should be poised for some solid growth. Investors take note. |
The Motley Fool
July 20, 2005
Stephen D. Simpson |
Pfizer's Long Road Back It took time for Pfizer to reach a trough and it will take time to climb out. But over the long haul this could prove to be a solid pick. |
The Motley Fool
July 20, 2005
Stephen D. Simpson |
Why Not Wyeth? Wyeth has turned itself around, but is it still an attractive big-pharma investment? |
| <Older 8521-8530 Newer> Return to current articles. |
